| scholarly article | Q13442814 |
| P50 | author | Alessandro Sette | Q28324161 |
| P2093 | author name string | E. Appella | |
| I. Kawashima | |||
| E. Celis | |||
| S. J. Hudson | |||
| K. Takesako | |||
| S. Southwood | |||
| V. Tsai | |||
| P2860 | cites work | Cytolytic T lymphocytes | Q40076423 |
| MHC ligands and peptide motifs: first listing | Q40612811 | ||
| Tumor antigens recognized by T lymphocytes | Q40661131 | ||
| The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects | Q40661193 | ||
| Peptides naturally presented by MHC class I molecules | Q40898177 | ||
| Identifying strategies for immune intervention | Q40907476 | ||
| Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC. | Q41113084 | ||
| Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules | Q41230821 | ||
| Epitope selection and development of peptide based vaccines to treat cancer | Q41236192 | ||
| Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs | Q41266882 | ||
| Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine | Q41327004 | ||
| A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. | Q41421781 | ||
| Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays | Q41450491 | ||
| Cancer vaccines based on the identification of genes encoding cancer regression antigens | Q41459252 | ||
| Synthetic antigenic peptides as a new strategy for immunotherapy of cancer | Q41623392 | ||
| A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E | Q42603854 | ||
| Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo | Q44708292 | ||
| Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. | Q45879847 | ||
| Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. | Q46430404 | ||
| Carcinoembryonic antigen in breast cancer patients: serum levels and disease progress | Q47876977 | ||
| Degenerate Cytotoxic T Cell Epitopes from P. falciparum Restricted by Multiple HLA-A and HLA-B Supertype Alleles | Q48037174 | ||
| Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy | Q53779081 | ||
| Tumor antigens | Q68132800 | ||
| Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues | Q68944840 | ||
| Clinical applications of carcinoembryonic antigen | Q70220165 | ||
| Expression of mage genes by non-small-cell lung carcinomas | Q72272098 | ||
| Do epitopes derived from autoantigens display low affinity for MHC class I? | Q73125378 | ||
| Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes | Q24680097 | ||
| Structure, chromosomal localization, and expression of 12 genes of the MAGE family | Q28238754 | ||
| Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha | Q28251443 | ||
| Identification and intracellular location of MAGE-3 gene product | Q28301817 | ||
| p53 mutations in human cancers | Q28302973 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins | Q30442847 | ||
| Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. | Q30463850 | ||
| Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles | Q34316159 | ||
| Sequence and expression pattern of the human MAGE2 gene | Q34347479 | ||
| Antigen processing and presentation by the class I major histocompatibility complex | Q34389698 | ||
| Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide | Q34765735 | ||
| Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes | Q35093159 | ||
| Proliferating dendritic cell progenitors in human blood | Q36363279 | ||
| Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines | Q36364998 | ||
| The peptide-binding motif for the human transporter associated with antigen processing | Q36365611 | ||
| Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes | Q36366680 | ||
| Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. | Q36376876 | ||
| Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. | Q36676048 | ||
| Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules | Q36741865 | ||
| Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide | Q37049451 | ||
| Carcinoembryonic antigen gene family: molecular biology and clinical perspectives | Q37469078 | ||
| The p53 tumour suppressor gene | Q37751892 | ||
| Antigen recognition by class I-restricted T lymphocytes | Q38201551 | ||
| Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis | Q39787946 | ||
| CEA-related antigens: molecular biology and clinical significance | Q39817736 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| adoptive immunotherapy | Q72138716 | ||
| P304 | page(s) | 1-14 | |
| P577 | publication date | 1998-01-01 | |
| P1433 | published in | Human Immunology | Q15709955 |
| P1476 | title | The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors | |
| P478 | volume | 59 |
| Q78336962 | A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18 |
| Q42645516 | A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes |
| Q39621147 | A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. |
| Q52038517 | A combined bioinformatic approach oriented to the analysis and design of peptides with high affinity to MHC class I molecules |
| Q40840298 | A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals |
| Q34380820 | A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines |
| Q36675454 | A review of vaccine clinical trials for non-small cell lung cancer |
| Q38633206 | Adjuvant HER2/neu peptide cancer vaccines in breast cancer |
| Q38296833 | An aptamer targeting shared tumor-specific peptide antigen of MAGE-A3 in multiple cancers |
| Q41787921 | An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform |
| Q46963588 | Analysis of HLA-A24-restricted peptides of carcinoembryonic antigen using a novel structure-based peptide-HLA docking algorithm |
| Q38262688 | Bioinformatics for cancer immunotherapy target discovery |
| Q64096332 | Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects |
| Q34956133 | Cellular immunity to the Her-2/neu protooncogene |
| Q36326582 | Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells |
| Q33218429 | Classification of A1- and A24-supertype molecules by analysis of their MHC-peptide binding repertoires |
| Q26745440 | Clinical Development of the E75 Vaccine in Breast Cancer |
| Q24804892 | Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells |
| Q40651254 | Cross‐Binding BetweenPlasmodium falciparumCTL Epitopes and HLA Class I Molecules |
| Q39966752 | Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia |
| Q33911460 | DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor |
| Q36459332 | De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. |
| Q36198607 | Dendritic cell-based immunotherapy for malignant gliomas |
| Q34661797 | Dendritic cell-based vaccines: barriers and opportunities |
| Q43269855 | Dendritic cells pulsed with GST-EGFR fusion protein: effect in antitumor immunity against head and neck squamous cell carcinoma |
| Q35207535 | Design of multi-epitope, analogue-based cancer vaccines |
| Q38800011 | Designing therapeutic cancer vaccines by mimicking viral infections |
| Q37776145 | Developing an Effective Breast Cancer Vaccine |
| Q51490010 | Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants |
| Q38305306 | Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. |
| Q92060838 | Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data |
| Q41503180 | Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. |
| Q77666977 | Frequencies of HER-2/neu overexpression relating to HLA haplotype in patients with gastric cancer |
| Q33315730 | HLA class I supertypes: a revised and updated classification |
| Q77174603 | HLA supertypes and supermotifs: a functional perspective on HLA polymorphism |
| Q33806895 | High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells |
| Q45284671 | Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors |
| Q40759589 | Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen |
| Q36367841 | Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes |
| Q30814677 | Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data |
| Q36870592 | Identification of T-cell epitopes for cancer immunotherapy |
| Q36886232 | Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. |
| Q36101780 | Identification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4. |
| Q39727327 | Identification of a novel peptide derived from the M-phase phosphoprotein 11 (MPP11) leukemic antigen recognized by human CD8+ cytotoxic T lymphocytes. |
| Q51008894 | ImMucin: A novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors |
| Q36011425 | Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients |
| Q50979402 | Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes |
| Q36786512 | Immunology and immunotherapy approaches for prostate cancer. |
| Q64100250 | In-silico design of a multi-epitope vaccine candidate against onchocerciasis and related filarial diseases |
| Q33574793 | Interaction of Bap31 and MHC class I molecules and their traffic out of the endoplasmic reticulum |
| Q52118864 | Knowledge-based grouping of modeled HLA peptide complexes |
| Q85059482 | MAGE-A3 and MAGE-A4 specific CD4+ T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes |
| Q31029658 | Majority of peptides binding HLA-A∗0201 with high affinity crossreact with other A2-supertype molecules |
| Q37832438 | Modulation of tumor immunity by therapeutic monoclonal antibodies |
| Q47965210 | Nomenclature for factors of the HLA system, 1998. |
| Q48758087 | Nomenclature for factors of the HLA system, 1998. |
| Q37902639 | Novel Immunotherapeutic Agents and Small Molecule Antagonists of Signalling Kinases for the Treatment of Metastatic Melanoma |
| Q37719552 | Patented cancer vaccines: the promising leads |
| Q38807849 | Peptide-Based Cancer Vaccine Strategies and Clinical Results |
| Q38293525 | Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer |
| Q48284592 | Potential mouse tumor model for pre-clinical testing of mage-specific breast cancer vaccines |
| Q42954755 | Prediction of HLA-A2-restricted CTL epitope specific to HCC by SYFPEITHI combined with polynomial method |
| Q34491734 | Profound tumor-specific Th2 bias in patients with malignant glioma |
| Q34253585 | Progress in human tumour immunology and immunotherapy |
| Q34789569 | Reassessing target antigens for adoptive T-cell therapy |
| Q35101735 | Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies |
| Q36471831 | Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles |
| Q40649080 | Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities |
| Q35209044 | Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination |
| Q36376346 | Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide |
| Q35918501 | T-cell epitope peptide vaccines. |
| Q38767662 | T-cell receptor-engineered T cells for cancer treatment: current status and future directions |
| Q38885965 | The development and use of the E75 (HER2 369-377) peptide vaccine |
| Q37483795 | The functioning antigens: beyond just as the immunological targets |
| Q35005926 | Tumor-specific shared antigenic peptides recognized by human T cells |
| Q37414561 | Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide |
| Q24801995 | Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition |
| Q57050167 | Utilizing TAPBPR to promote exogenous peptide loading onto cell surface MHC I molecules |
Search more.